

# Novel Anti-inflammatory Biological Drug Candidate

## TECHNOLOGY AVAILABLE FOR TRANSFER

### UNMET NEED & OPPORTUNITY

- Biologics and Immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drug classes that will play key role in the market in future.<sup>1</sup>
- The demand for anti-inflammatory drugs has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs.
- The rising demand for advanced drugs is likely to create lucrative growth opportunities for the Global Anti-inflammatory Drugs.
- Global Anti-inflammatory therapeutics market is projected to US\$ 130.6 Billion by 2026 with CAGR of 8.5% throughout the forecast period from 2018 to 2026.
- Commercially available Biologic Anti-inflammatory drugs are used essentially for Arthritis patients and can be categorized in three a. TNF inhibitor, b. B-cell inhibitors, and c. Interleukin-1 blockers.
- The present invention provides a broad-spectrum novel, safer anti-inflammatory biological candidate that targets inhibition of Mast cells.

### TECHNOLOGY

- The technology is based on mast cells inhibition by a recombinant protein based drug – SM01 isolated from *M. tuberculosis*
- SM01 is a member of the PPE family of Mycobacterium tuberculosis. The present drug candidate is truncated smaller version of SM01 sequence for ease of delivery.
- The designed SM01 short protein have been shown to help fast recovery from inflammation in mice paw which was monitored for 21days after single application as demonstrated in Figure 1.


#### References

1. <https://www.researchandmarkets.com/reports/4564280/global-anti-inflammatory-therapeutics-market>
2. <https://www.medgadget.com/2019/08/anti-inflammatory-therapeutics-market-perception-to-cross-106-1-bn-by-2020.html>

### KEY FEATURES

The broad-spectrum anti-inflammatory biological drug candidate is:

- Non-steroidal
- Mast cell inhibitor (disruption of first line inflammatory effect)
- Effective in single injectable dose
- Enables scar-less wound



### STAGE OF DEVELOPMENT

- The technology is at R&D stage with primary proof of concept data.

### INTELLECTUAL PROPERTY

Patent application filed in India in 2018

### LICENSING OPPORTUNITY

BCIL is looking for a suitable industrial partner for development and commercialization of Anti-inflammatory drug candidate

#### CONTACT:

**Dr. Yogmaya Verma**

Deputy Manager

BIOTECH CONSORTIUM INDIA LIMITED

V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi:110 002

Phone: +91-11-23219064-67 Fax: +91-11-23219063

Email: [yogmaya@biotech.co.in](mailto:yogmaya@biotech.co.in) & [info.bcil@nic.in](mailto:info.bcil@nic.in)

Website: [www.bcil.nic.in](http://www.bcil.nic.in)